{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:34:39Z","timestamp":1790116479844,"version":"4.0.1"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2017,6,2]],"date-time":"2017-06-02T00:00:00Z","timestamp":1496361600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s00277-017-3032-8","type":"journal-article","created":{"date-parts":[[2017,6,2]],"date-time":"2017-06-02T14:19:05Z","timestamp":1496413145000},"page":"1411-1413","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Successful treatment with azacitidine for the simultaneous occurrence of multiple myeloma and acute myeloid leukemia with concomitant del(5q) and the JAK2 V617F mutation"],"prefix":"10.1007","volume":"96","author":[{"given":"Satoko","family":"Oka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaharu","family":"Nohgawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,2]]},"reference":[{"key":"3032_CR1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1046\/j.1365-2141.2001.03073.x","volume":"115","author":"Y Kita-Sasai","year":"2001","unstructured":"Kita-Sasai Y, Horiike S, Misawa S et al (2001) International prognostic scoring system and TP53 mutations are independent prognostic indicators for patients with myelodysplastic syndrome. Br J Haematol 115:309\u2013312","journal-title":"Br J Haematol"},{"key":"3032_CR2","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1038\/leu.2016.111","volume":"30","author":"M Mossner","year":"2016","unstructured":"Mossner M, Jann JC, Nowak D et al (2016) Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the German MDS study group (GMDS). Leukemia 30:1956\u20131959","journal-title":"Leukemia"},{"key":"3032_CR3","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1182\/blood-2008-12-193458","volume":"114","author":"D Reece","year":"2009","unstructured":"Reece D, Song KW, Fu T et al (2009) Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood 114:522\u2013525","journal-title":"Blood"},{"key":"3032_CR4","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1038\/leu.2010.175","volume":"24","author":"MA Dimopoulos","year":"2010","unstructured":"Dimopoulos MA, Kastritis E, Christoulas D et al (2010) Treatment of patients with relapsed\/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. Leukemia 24:1769\u20131778","journal-title":"Leukemia"},{"key":"3032_CR5","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3324\/haematol.2013.098103","volume":"99","author":"L Saft","year":"2014","unstructured":"Saft L, Karimi M, Ghaderi M et al (2014) p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q). Haematologica 99:1041\u20131049","journal-title":"Haematologica"},{"key":"3032_CR6","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.clml.2011.04.001","volume":"11","author":"AE Eskazan","year":"2011","unstructured":"Eskazan AE, Ongoren S, Ar MC, Soysal T, Ferhanoglu B, Aki H, Aydin Y (2011) Essential thrombocythemia and multiple myeloma: two rare diseases in one patient. Clin Lymphoma Myeloma Leuk 11:442\u2013445","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3032_CR7","doi-asserted-by":"crossref","first-page":"860","DOI":"10.3324\/haematol.12261","volume":"93","author":"T Khong","year":"2008","unstructured":"Khong T, Sharkey J, Spencer A (2008) The effect of azacitidine on interleukin-6 signaling and nuclear factor-kappaB activation and its in vitro and in vivo activity against multiple myeloma. Haematologica 93:860\u2013869","journal-title":"Haematologica"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-017-3032-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-017-3032-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-017-3032-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T02:28:34Z","timestamp":1498271314000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-017-3032-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,2]]},"references-count":7,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["3032"],"URL":"https:\/\/doi.org\/10.1007\/s00277-017-3032-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,2]]}}}